How to Isolate Bioactive Metabolites Reliably
Learn how to isolate bioactive metabolites through bioactivity-guided fractionation, analytical characterization, and disciplined candidate selection steps.
Author Archive for: GenBio Inc.
Entries by GenBio Inc.
How to Validate Natural Product Hits Reliably
A disciplined framework to validate natural product hits through reproducibility, chemical characterization, orthogonal assays, and candidate decisions.
How Bioactive Compounds Become Candidates
Bioactive compounds require more than an assay signal. See how disciplined fractionation, characterization, and validation inform candidate selection plans.
Biotechnology Natural Products Investment Trends
Biotechnology natural products investment trends favor evidence-led platforms, reproducible data, and staged programs with credible development paths rigor.
Natural Product Drug Discovery Trends Reshaping R&D
Natural product drug discovery trends are redefining how teams prioritize, validate, and advance complex bioactive materials into candidates carefully.
Lead Prioritization Workflow for Natural Products
A disciplined lead prioritization workflow helps natural-product programs convert early activity into reproducible, development-ready candidate decisions.
Emerging Natural Product Modalities in Biotech
A disciplined view of emerging natural product modalities, from extracts to characterized candidates, reproducible evidence, and development planning.
Metabolomics vs Fractionation: What Each Proves
Metabolomics vs fractionation: see how profiling and bioactivity-guided isolation provide distinct evidence for early natural-product candidate selection.
What Biological Extract Characterization Proves
Biological extract characterization establishes active constituents, reproducibility, and decision-ready evidence for disciplined candidate selection.
Natural Product Development Planning, Evidence First
Natural product development planning aligns discovery evidence, reproducibility, candidate selection, and regulatory strategy before capital commitment.
